Mirosław Zieliński, president of the Polish National Forum for the Therapy of rare diseases (ORPHAN), the representative voice for 35 Polish rare disease associations, discusses the implications of the introduction of a national rare disease plan and the need to improve rare disease diagnostics. Furthermore, he highlights the importance of a separate orphan drug budget that takes into account different factors as well as the future aspirations of the organization.
As the president, could you introduce ORPHAN to our international audience?
"The national program has been developed based on the initial model designed by the European project for rare disease plans."
